Michael Zuehlsdorf - Concepedia

Concepedia

Author

Michael Zuehlsdorf

Bayer (Germany)

Also Known As

M ZUEHLSDORF, M Zuehlsdorf, M. Zuehlsdorf, Michael Zuehlsdorf

31

Publications

2.9K

Citations

16

H-Index

27

Concepts

All Affiliations

Bayer (Germany)Johns Hopkins University University of Münster

MZ

About

Michael Zuehlsdorf is an author at Bayer (Germany) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.5K
2	Health Sciences	2	2	279
3	Cell Biology	1	1	26
4	Clinical Nutrition	1	1	253
5	Immunology	1	1	27

Michael Zuehlsdorf

×

18

Publications

2.9K

Citations

15

H-Index

	Year	Citations
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Dagmar Kubitza, Michael Becka, Barbara Voith, Clinical Pharmacology & Therapeutics	2005	652
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects Dagmar Kubitza, Michael Becka, Georg Wensing, European Journal of Clinical Pharmacology Therapeutic Drug MonitoringPharmacologyClinical PharmacologyPharmacotherapyHealthy Male Subjects	2005	648
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf, The Journal of Clinical Pharmacology ObesityThrombosisDose AdjustmentHealthy SubjectsCardiovascular Disease	2007	327
Effect of Food, an Antacid, and the H<sub>2</sub> Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf, The Journal of Clinical Pharmacology NutritionFood Interaction StudiesHealthy SubjectsPharmacological StudyGastrointestinal Pharmacology	2006	253
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin Dagmar Kubitza, Michael Becka, Wolfgang Mueck, The Journal of Clinical Pharmacology PharmacotherapyPlatelet AggregationPharmacodynamic ModelingMolecular PharmacologyThrombosis	2006	181
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects Wolfgang Mueck, Michael Becka, Dagmar Kubitza, International Journal of Clinical Pharmacology and Therapeutics	2007	178
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen Dagmar Kubitza, Michael Becka, Wolfgang Mueck, British Journal of Clinical Pharmacology	2006	158
CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4- hydroperoxycyclophosphamide-purged bone marrow SD Rowley, Michael Zuehlsdorf, HG Braine, Blood	1987	149
The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Blood	2006	77
Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis Jens‐Michael Jensen, Andreas Scherer, C. A. Wanke, Allergy	2011	72

Page 1